Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.80 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | GPR183 | P32249 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23682772 | 0.89 | L3MBTL3 (1.00) | MBTD1L3MBTL3ALDH1A1HPGDKDM4E | |
| SCHEMBL17007413 | 0.85 | MBTD1 (0.79) | MBTD1L3MBTL3ALDH1A1MEN1KMT2A | |
| SCHEMBL3387440 | 0.82 | MBTD1 (0.70) | MBTD1L3MBTL3ALDH1A1MEN1KMT2A | |
| SCHEMBL31388283 | 0.81 | ALDH1A1 (0.84) | ALDH1A1MEN1KMT2AKDM4EGAA | |
| SCHEMBL263317 | 0.81 | MBTD1 (0.73) | MBTD1L3MBTL3ALDH1A1MEN1KMT2A | |
| SCHEMBL3384758 | 0.81 | MBTD1 (0.68) | MBTD1L3MBTL3ALDH1A1MEN1KMT2A | |
| SCHEMBL3711340 | 0.81 | MBTD1 (0.68) | MBTD1L3MBTL3ALDH1A1MEN1KMT2A | |
| SCHEMBL2379666 | 0.80 | POLB (0.65) | MBTD1L3MBTL3MEN1KMT2AGAA | |
| SCHEMBL265068 | 0.80 | MBTD1 (0.71) | MBTD1L3MBTL3ALDH1A1MEN1KMT2A | |
| SCHEMBL3391959 | 0.80 | MBTD1 (0.71) | MBTD1L3MBTL3ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846687-B2 | Pyrazine compounds as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20120214800-A1 | Organic Compounds | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| CN-102036961-A | Pyridine and pyrazine compounds as PI3K inhibitors | NOVARTIS AG | 2011-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214800-A1 | Organic Compounds | AR, TRPA1, IL33 | MBTD1 3075/4885L3MBTL3 4093/4885ALDH1A1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.